Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals focuses on treating metabolic dysfunction-associated steatohepatitis (MASH) with Rezdiffra, a liver‑directed thyroid hormone receptor β agonist in Phase III trials. The company partners with Roche and targets a growing MASH market.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 528
- HQ: West Conshohocken
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.